Payment overview · 2025
General Payments
$38.76
2 reported records · 2 companies
Healthcare provider profile · identity verified
Stephen Walter Williams, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ANTHEM, AZ · NPI 1902933823
Verified facts
What the public records show
CMS Open Payments records show Stephen Walter Williams, D.O. received $38.76 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.14 | 52.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.62 | 48.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.76 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 88 |
| Lisinopril | Lisinopril | 221 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 66 |
| Losartan Potassium | Losartan Potassium | 202 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 44 |
| Liothyronine Sodium | Liothyronine Sodium | 133 | 36 |
| Omeprazole | Omeprazole | 125 | 35 |
| Progesterone | Progesterone, Micronized | 118 | 35 |
| Gabapentin | Gabapentin | 113 | 31 |
| Metformin Hcl Er | Metformin Hcl | 99 | 36 |
| Simvastatin | Simvastatin | 98 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 31 |
| Bupropion Xl | Bupropion Hcl | 94 | 21 |
| Lorazepam | Lorazepam | 93 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 30 |
| Estradiol | Estradiol | 91 | 23 |
| Montelukast Sodium | Montelukast Sodium | 91 | 30 |
| Trazodone Hcl | Trazodone Hcl | 89 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 40 |
| Alprazolam | Alprazolam | 77 | 21 |
| Furosemide | Furosemide | 75 | 25 |
| Clonazepam | Clonazepam | 74 | 13 |
| Tramadol Hcl | Tramadol Hcl | 74 | 18 |
| Allopurinol | Allopurinol | 72 | 19 |
| Meloxicam | Meloxicam | 72 | 30 |
| Eliquis | Apixaban | 70 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Telmisartan | Telmisartan | 67 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 15 |
| Metformin Hcl | Metformin Hcl | 63 | 18 |
| Prednisone | Prednisone | 59 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 14 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Finasteride | Finasteride | 48 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Azithromycin | Azithromycin | 41 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 15 |
| Potassium Chloride | Potassium Chloride | 41 | 17 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 15 |
| Ozempic | Semaglutide | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 13 |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Famotidine | Famotidine | 29 | 11 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.76 · 2 records | PFIZER INC. | ABRYSVO, COMIRNATY, PREVNAR 20, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error